Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in the ISAR-Absorb MI trial

[1]  Seung‐Jung Park,et al.  Bioresorbable Vascular Scaffolds Versus Drug-Eluting Stents for Diffuse Long Coronary Narrowings. , 2020, The American journal of cardiology.

[2]  P. Serruys,et al.  Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study. , 2019, JAMA cardiology.

[3]  H. Schunkert,et al.  Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial , 2018, European heart journal.

[4]  P. Serruys,et al.  Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents. A pooled analysis of individual patient data from 2 randomized trials. , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  G. Stone,et al.  Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial , 2018, The Lancet.

[6]  P. Serruys,et al.  Quality difference of neointima following the implantation of everolimus-eluting bioresorbable scaffolds and metallic stents in patients with ST-elevation myocardial infarction: quantitative assessments by light intensity, light attenuation, and backscatter on optical coherence tomography in the TRO , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[7]  M. Joner,et al.  Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study. , 2018, International journal of cardiology.

[8]  L. Räber,et al.  Mechanisms of Very Late Bioresorbable Scaffold Thrombosis: The INVEST Registry. , 2017, Journal of the American College of Cardiology.

[9]  R. Gao.  The ABSORB China trial , 2017 .

[10]  G. Stone,et al.  Coronary balloon angioplasty, stents, and scaffolds , 2017, The Lancet.

[11]  J. Tijssen,et al.  Bioresorbable Scaffolds versus Metallic Stents in Routine PCI , 2017, The New England journal of medicine.

[12]  Joanna J Wykrzykowska,et al.  Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. , 2017, The New England journal of medicine.

[13]  Bernard Chevalier,et al.  Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial , 2016, The Lancet.

[14]  P. Serruys,et al.  The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. , 2016, JACC. Cardiovascular interventions.

[15]  P. Serruys,et al.  Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction—TROFI II trial , 2015, European heart journal.

[16]  W. Cheong,et al.  A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. , 2015, European heart journal.

[17]  W. Cheong,et al.  Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. , 2015, Journal of the American College of Cardiology.

[18]  P. Teirstein,et al.  Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. , 2015, The New England journal of medicine.

[19]  M. Togni,et al.  Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. , 2015, Journal of the American College of Cardiology.

[20]  M. Joner,et al.  Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography , 2014, The International Journal of Cardiovascular Imaging.

[21]  Michael Joner,et al.  Tissue Characterization After Drug-Eluting Stent Implantation Using Optical Coherence Tomography , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[22]  Patrick W Serruys,et al.  Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? , 2012, European heart journal.

[23]  Akiko Maehara,et al.  Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. , 2012, Journal of the American College of Cardiology.

[24]  I. Penn,et al.  Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study) , 1998, European heart journal.